MG
AGRX

Michael Gelband’s Agile Therapeutics AGRX Stock Holding History

Michael Gelband’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5
Closed -$10K – 2752
2021
Q3 		$10K Sell
5
-36
-88% -$81.5K ﹤0.01% 2023
2021
Q2 		$109K Buy
41
+32
+356% +$106K ﹤0.01% 2133
2021
Q1 		$37K Buy
+9
New +$48.6K ﹤0.01% 2044
2020
Q2 		– Sell
-19
Closed -$71K – 2112
2020
Q1 		$71K Sell
19
-26
-58% -$149K ﹤0.01% 931
2019
Q4 		$223K Buy
+45
New +$157K ﹤0.01% 1295

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's AGRX Position: Q4 2021 in Review

Michael Gelband sold out of Agile Therapeutics (AGRX) in Q4 2021, closing a stake of 5 shares — an estimated $10K sold.

Michael Gelband first reported a position in AGRX in Q4 2019 and held it in 5 quarters. The position peaked at $223K in Q4 2019. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2021.

  • Michael Gelband reported no remaining Agile Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Michael Gelband sold 5 Agile Therapeutics shares in Q4 2021, an estimated $10K.
  • Michael Gelband first reported a position in Agile Therapeutics in Q4 2019 and held it in 5 quarters.
  • Michael Gelband's Agile Therapeutics position peaked at $223K in Q4 2019.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.